Abstract：
Compared to the risks inherent in pregnancy and daily activities of living, the increased risk of nonfatal venous thromboembolism (VTE) among users of oral contraceptives (OCs) containing desogestrel and gestodene is relatively benign. About 20-30 cases of nonfatal VTE per 100,000 users of third-generation OCs containing these progestins can be expected compared to 10-15 cases per 100,000 users of levonorgestrel-containing OCs. Pregnancy, on the other hand, confers an increased risk of about 60 cases of nonfatal VTE per 100,000 women. Since OCs remain the most popular reversible method of birth control, their discontinuation because of VTE concerns would have serious public health consequences in terms of unwanted pregnancy prevention. Moreover, OCs confer a number of noncontraceptive health benefits, including protection against ovarian and endometrial cancer, osteoporosis, benign breast disease, ovarian cysts, and pelvic inflammatory disease. The lives saved by OCs should be considered in any analysis of the small VTE risk they may impart.
摘要：
与怀孕和日常生活中固有的风险相比，使用含去氧孕烯和孕酮的口服避孕药(OCs)的非致死性静脉血栓栓塞(VTE)的患者发生非致死性静脉血栓栓塞(VTE)的风险相对良性.预计每100,000名含有这些孕激素的第三代OCs用户中大约有20-30例非致命VTE病例，而每100,000名含有左炔诺孕酮的OCs用户中大约有10-15例。怀孕,另一方面,每100,000名女性约60例非致死性VTE的风险增加.由于OCs仍然是最流行的可逆节育方法，由于对VTE的担忧而停药将对预防意外怀孕造成严重的公共卫生后果.此外，OCs赋予许多非避孕健康益处，包括预防卵巢癌和子宫内膜癌，骨质疏松,良性乳腺疾病,卵巢囊肿,和盆腔炎.在分析OCs可能带来的微小VTE风险时，应考虑OCs挽救的生命。
